What is it about?

We identified predictors of ≥15% body weight reduction with tirzepatide treatment and described characteristics of people with type 2 diabetes who achieved different categorical measures of body weight reduction across SURPASS 1-4.

Featured Image

Read the Original

This page is a summary of: Predictors of ≥15% Weight Reduction and Associated Changes in Cardiometabolic Risk Factors With Tirzepatide in Adults With Type 2 Diabetes in SURPASS 1–4, Diabetes Care, October 2023, American Diabetes Association,
DOI: 10.2337/dc23-1135.
You can read the full text:

Read

Contributors

Be the first to contribute to this page